


Edited by
Jie Jack Li
Douglas S. Johnson



Contents

Preface	xi
Contributors	xiii
 I. Infectious Diseases	 1
 Chapter 1. Raltegravir (Isentress): The First-in-Class HIV-1 Integrase Inhibitor	 3
<i>Julianne A. Hunt</i>	
1.1 Background	3
1.2 Pharmacology	5
1.3 Structure–Activity Relationship (SAR)	6
1.4 Pharmacokinetics and Drug Metabolism	8
1.5 Efficacy and Safety	9
1.6 Syntheses	10
1.7 References	13
 Chapter 2. Maraviroc (Selzentry): The First-in-Class CCR5 Antagonist for the Treatment of HIV	 17
<i>David Price</i>	
2.1 Background	17
2.2 Structure–Activity Relationship (SAR)	19
2.3 Pharmacokinetics and Safety	21
2.4 Syntheses	22
2.5 References	27
 Chapter 3. Darunavir (Prezista): A HIV-1 Protease Inhibitor for Treatment of Multidrug Resistant HIV	 29
<i>Arun K. Ghosh and Cuthbert D. Martyr</i>	
3.1 Background	29
3.2 Pharmacology	32
3.3 Structure–Activity Relationship (SAR)	32
3.4 Pharmacokinetics and Drug Metabolism	33
3.5 Efficacy and Safety	33
3.6 Syntheses	34
3.7 References	42

II. Cancer

Chapter 4. Decitabine (Dacogen): A DNA Methyltransferase Inhibitor for Cancer 47

Jennifer A. Van Camp

4.1	Background	47
4.2	Pharmacology	49
4.3	Structure–Activity Relationship (SAR)	49
4.4	Pharmacokinetics and Drug Metabolism	50
4.5	Efficacy and Safety	50
4.6	Syntheses	51
4.7	References	54

Chapter 5. Capecitabine (Xeloda): An Oral Chemotherapy Agent 57

R. Jason Herr

5.1	Background	57
5.2	Pharmacology	60
5.3	Structure–Activity Relationship (SAR)	62
5.4	Pharmacokinetics and Efficacy	63
5.5	Syntheses	64
5.6	References	70

Chapter 6. Sorafenib (Nexavar): A Multikinase Inhibitor for Advanced Renal Cell Carcinoma and Unresectable Hepatocellular Carcinoma 73

Shuanghua Hu and Yazhong Huang

6.1	Background	73
6.2	Pharmacology	75
6.3	Structure–Activity Relationship (SAR)	77
6.4	Pharmacokinetics and Drug Metabolism	78
6.5	Efficacy and Safety	78
6.6	Syntheses	79
6.7	References	84

Chapter 7. Sunitinib (Sutent): An Angiogenesis Inhibitor

Martin Pettersson

7.1	Background	87
7.2	Discovery and Development	89
7.3	Syntheses	91
	7.3.1 Discovery Route	91
	7.3.2 Process Route	92
7.4	References	97

Chapter 8. Bortezomib (Velcade): A First-in-Class Proteasome Inhibitor 99

Benjamin S. Greener and David S. Millan

8.1	Background	99
8.2	Pharmacology	101
8.3	Structure–Activity Relationship (SAR)	102
8.4	Pharmacokinetics and Drug Metabolism	104
8.5	Efficacy and Safety	104
8.6	Syntheses	105
8.7	References	109

Chapter 9. Pazopanib (Votrient): A VEGFR Tyrosine Kinase Inhibitor for Cancer 111

Ji Zhang and Jie Jack Li

9.1	Background	111
9.2	Pharmacology	113
9.3	Structure–Activity Relationship (SAR)	114
9.4	Pharmacokinetics and Drug Metabolism	117
9.5	Efficacy and Safety	118
9.6	Syntheses	118
9.7	Other VEGFR Inhibitors in Development: Vandetanib and Cediranib	120
9.8	References	121

III. Cardiovascular and Metabolic Diseases 123

Chapter 10. Sitagliptin (Januvia): A Treatment for Type 2 Diabetes 125

Scott D. Edmondson, Feng Xu, and Joseph D. Armstrong III

10.1	Background	125
10.2	Pharmacology	126
10.3	Structure–Activity Relationship (SAR)	127
10.4	Pharmacokinetics and Drug Metabolism	128
10.5	Efficacy and Safety	129
10.6	Syntheses	130
10.7	References	138

Chapter 11. Aliskiren (Tekturna), The First-in-Class Renin Inhibitor for Hypertension 141

Victor J. Cee

11.1	Background	141
11.2	Pharmacology	144
11.3	Structure–Activity Relationship (SAR)	145
11.4	Pharmacokinetics and Drug Metabolism	146
11.5	Efficacy and Safety	147
11.6	Syntheses	148
11.7	References	156

Chapter 12. Vernakalant (Kynapid): An Investigational Drug for the Treatment of Atrial Fibrillation 159

David L. Gray

12.1	Background	159
12.2	Pharmacology	163
12.3	Structure–Activity Relationship (SAR)	163
12.4	Pharmacokinetics and Drug Metabolism	164
12.5	Efficacy and Safety	165
12.6	Syntheses	166
12.7	References	171

Chapter 13. Conivaptan (Vaprisol), Vasopressin V1a and V2 Antagonist for Hyponatremia 175

Brian A. Lanman

13.1	Background	175
13.2	Pharmacology	177
13.3	Structure–Activity Relationship (SAR)	179
13.4	Pharmacokinetics and Drug Metabolism	181
13.5	Efficacy and Safety	182
13.6	Syntheses	183
13.7	References	189

Chapter 14. Rivaroxaban (Xarelto): A Factor Xa Inhibitor for the Treatment of Thrombotic Events 191

Ji Zhang and Jason Crawford

14.1	Background	191
14.2	Pharmacology	193
14.3	Structure–Activity Relationship (SAR)	194
14.4	Pharmacokinetics and Drug Metabolism	196
14.5	Efficacy and Safety	197
14.6	Syntheses	198
14.7	Compounds in Development: Apixaban and Otamixaban	203
14.8	References	204

Chapter 15. Endothelin Antagonists for the Treatment of Pulmonary Arterial Hypertension 207

David J. Edmonds

15.1	Background	208
15.2	Treatment of PAH	209
15.3	Endothelin Antagonists	211
15.4	Synthesis of Bosentan	215
15.5	Synthesis of Sitaxsentan	217
15.6	Synthesis of Ambrisentan	219
15.7	Conclusion	221
15.8	References	221

IV. Central Nervous System Diseases 225

Chapter 16. Varenicline (Chantix), An $\alpha 4\beta 2$ Nicotinic Receptor Partial Agonist for Smoking Cessation 227

Jotham W. Coe, Frank R. Busch and Robert A. Singer

16.1	Background	227
16.2	Discovery Chemistry Program	229
16.3	Pharmacology	231
16.4	Pharmacokinetics and Drug Metabolism	231
16.5	Efficacy and Safety	232
16.6	Syntheses	232
16.7	References	244

Chapter 17. Donepezil, Rivastigmine, and Galantamine: Cholinesterase Inhibitors for Alzheimer Disease 249

Subas Sakya and Kapil Karki

17.1	Background	250
17.2	Pharmacology	251
17.3	Structure–Activity Relationship (SAR)	253
17.4	Pharmacokinetics and Drug Metabolism	256
17.5	Efficacy and Safety	258
17.6	Synthesis of Donepezil	259
17.7	Synthesis of Rivastigmine	262
17.8	Synthesis of Galantamine	265
17.9	References	271

Chapter 18. Aprepitant (Emend): A NK₁ Receptor Antagonist for the Treatment of Postchemotherapy Emesis 275

John A. Lowe III

18.1	Background	275
18.2	<i>In Vitro</i> Pharmacology and Structure–Activity Relationships	279
18.3	<i>In Vivo</i> Pharmacology	281
18.4	Pharmacokinetics and Drug Metabolism	282
18.5	Efficacy and Safety	282
18.6	Syntheses	283
18.7	References	289

Chapter 19. Armodafinil (Nuvigil): A Psychostimulant for the Treatment of Narcolepsy 291

Ji Zhang and Jason Crawford

19.1	Background	291
19.2	Pharmacology	293
19.3	Pharmacokinetics and Drug Metabolism	294
19.4	Efficacy and Safety	295
19.5	Synthesis	296
19.6	References	303

V. Miscellaneous 307

Chapter 20. Raloxifene (Evista): A Selective Estrogen Receptor Modulator (SERM) 309

Marta Piñeiro-Núñez

20.1	Background	309
20.2	Mechanism of Action	313
20.3	Pharmacokinetics and Drug Metabolism	313
20.4	Efficacy and Safety	314
20.5	Syntheses	315
20.6	References	325

Chapter 21. Latanoprost (Xalatan): A Prostanoid FP Agonist for Glaucoma 329

Sajiv K. Nair and Kevin E. Henegar

21.1	Background	329
21.2	Syntheses	331
21.3	References	337

Index 339